Breast Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Breast Cancer Market Outlook

Thelansis's "Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Breast Cancer Overview

Breast cancer is the most common malignancy in women worldwide, classified into hormone receptor-positive (HR+), HER2-positive, and triple-negative (TNBC) subtypes. Early-stage disease is managed with surgery, radiation, and subtype-specific adjuvant systemic therapy. In advanced disease, precision medicine has transformed care: endocrine therapy plus CDK4/6 inhibitors is standard for HR+ disease; HER2-targeted therapies and ADCs (trastuzumab deruxtecan, T-DM1) are central for HER2+ and HER2-low tumors; and sacituzumab govitecan and immunotherapy (pembrolizumab for PD-L1+ TNBC) provide new options in TNBC. Chemotherapy remains important, especially in aggressive disease, while genomic testing (e.g., BRCA mutations) guides PARP inhibitor use. Prevention and early detection through screening continue to underpin global strategies.

Key Highlights

• In Germany, survival-adjusted prevalent Breast Cancer cases are projected to increase from 3,692,865 in 2025 to 3,949,454 by 2035.
• Breast cancer remains the most prevalent cancer indication among women with improving survival outcomes.
• Increasing use of precision oncology and CDK4/6-targeted therapies is reshaping treatment standards.
• Persistent unmet need exists in metastatic and treatment-resistant breast cancer subtypes.

Market Overview

• The France Breast Cancer market is projected to grow from USD 2.1 billion in 2025 to USD 4.8 billion by 2035.
• Market growth is driven by strong uptake of targeted therapies, biologics, and ADCs.
• Future growth will depend on innovation in HER2-low, HR-positive, and triple-negative breast cancer therapies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Pfizer
• Merck Sharp & Dohme LLC
• Boundless Bio, Inc.
• Sichuan Baili Pharmaceutical Co., Ltd.
• MedSIR
• ExpreS2ion Biotechnologies
• Stemline Therapeutics, Inc.
• Genentech, Inc.
• Cellectar Biosciences, Inc.
• SURGE Therapeutics
• Eli Lilly and Company
• Celcuity Inc
• Arvinas Estrogen Receptor, Inc.
• Tolmar Inc.
• Jazz Pharmaceuticals
• Hoffmann-La Roche
• Regor Pharmaceuticals Inc.
• AstraZeneca
• Eisai Inc.
• SCRI Development Innovations, LLC
• Beijing Wehand-Bio Pharmaceutical Co., Ltd.
• Shandong Suncadia Medicine Co., Ltd.
• InventisBio Co., Ltd
• Daiichi Sankyo
• TransThera Sciences (Nanjing), Inc.
• Atridia Pty Ltd.
• Novartis Pharmaceuticals
• Olema Pharmaceuticals, Inc.
• Greenwich LifeSciences, Inc.
• Incyclix Bio